-
公开(公告)号：US10035860B2
公开(公告)日：2018-07-31
申请号：US14772863
申请日：2014-03-14
Applicant: Biogen MA Inc.
Inventor： Shelia M. Violette , Paul H. Weinreb , Timothy David Jones , Francis Joseph Carr , Anja Sibylle Tessarz
IPC: A61K39/395 , C07K16/00 , C07K16/46 , C07K16/28 , G01N33/53
CPC classification number: C07K16/2839 , C07K2317/14 , C07K2317/24 , C07K2317/565 , G01N33/5308 , G01N2800/00
Abstract: Humanized antibodies and antibody fragments thereof that bind to αvβ6 are disclosed. Also disclosed are methods of using these antibodies and antibody fragments to diagnose, treat, and/or prevent αvβ6-mediated diseases such as acute tissue injury, fibrosis, and cancer.
-
公开(公告)号：US10035859B2
公开(公告)日：2018-07-31
申请号：US14772512
申请日：2014-03-14
Applicant: Biogen MA Inc.
Inventor： Shelia M. Violette , Paul H. Weinreb , Timothy David Jones , Francis Joseph Carr , Anja Sibylle Tessarz
IPC: A61K39/395 , C07K16/00 , C07K16/46 , C07K16/28
CPC classification number: C07K16/2839 , C07K16/2842 , C07K2317/24 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/76 , C07K2317/92
Abstract: Humanized antibodies and antibody fragments thereof that bind to αvβ6 are disclosed. Also disclosed are methods of using these antibodies and antibody fragments to treat or prevent αvβ6-mediated diseases such as fibrosis and cancer.
-
公开(公告)号：US20160031992A1
公开(公告)日：2016-02-04
申请号：US14772512
申请日：2014-03-14
Applicant: Biogen MA Inc.
Inventor： Shelia M. Violette , Paul H. Weinreb , Timothy David Jones , Francis Joseph Carr , Anja Sibylle Tessarz
IPC: C07K16/28
CPC classification number: C07K16/2839 , C07K16/2842 , C07K2317/24 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/76 , C07K2317/92
Abstract: Humanized antibodies and antibody fragments thereof that bind to αvβ6 are disclosed. Also disclosed are methods of using these antibodies and antibody fragments to treat or prevent αvβ6-mediated diseases such as fibrosis and cancer.
Abstract translation: 公开了结合αv＆bgr6的人源化抗体及其抗体片段。 还公开了使用这些抗体和抗体片段来治疗或预防αvβb介导的疾病如纤维化和癌症的方法。
-
公开(公告)号：US20170369560A1
公开(公告)日：2017-12-28
申请号：US15427843
申请日：2017-02-08
Applicant: Biogen MA Inc. , Biogen International Neuroscience GmbH
Inventor： Paul H. Weinreb , Feng Chen , Ellen A. Garber Stark , Jan Grimm , Fabio Montrasio
CPC classification number: C07K16/18 , A61K39/3955 , A61K45/06 , A61K49/00 , A61K49/16 , A61K2039/505 , C07K2317/14 , C07K2317/21 , C07K2317/24 , C07K2317/30 , C07K2317/34 , C07K2317/41 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/71 , C07K2317/92 , C07K2317/94 , G01N33/6896 , G01N2333/47 , G01N2800/2814
Abstract: Provided are novel human tau-specific antibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for tau are also disclosed. The antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for tau targeted immunotherapy and diagnosis, respectively.
-
公开(公告)号：US09598484B2
公开(公告)日：2017-03-21
申请号：US14654176
申请日：2013-12-20
Applicant: Biogen MA Inc. , Biogen International Neuroscience GmbH
Inventor： Paul H. Weinreb , Feng Chen , Ellen A. Garber , Jan Grimm , Fabio Montrasio
CPC classification number: C07K16/18 , A61K39/3955 , A61K45/06 , A61K49/00 , A61K49/16 , A61K2039/505 , C07K2317/14 , C07K2317/21 , C07K2317/24 , C07K2317/30 , C07K2317/34 , C07K2317/41 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/71 , C07K2317/92 , C07K2317/94 , G01N33/6896 , G01N2333/47 , G01N2800/2814
Abstract: Provided are human tau-specific antibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for tau are also disclosed. The antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for tau targeted immunotherapy and diagnosis, respectively.
-
Patent Agency Ranking
公开(公告)号：US20160137739A1
公开(公告)日：2016-05-19
申请号：US14891491
申请日：2014-05-30
Applicant: BIOGEN MA INC.
Inventor： Heather A. Arnett , Sabine S. Escobar , Chadwick T. King , Ai Ching Lim , Saravanakumar Narayanan , Paul H. Weinreb , Nels E. Pederson
IPC: C07K16/28
CPC classification number: C07K16/2866 , A61K39/395 , C07K16/244 , C07K16/248 , C07K16/28 , C07K2317/21 , C07K2317/515 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92
Abstract: The invention provides anti-oncostatin M receptor-β (OSMR) antigen binding proteins. e.g., antibodies and functional fragments, derivatives, muteins, and variants thereof. OSMR antigen binding proteins interfere with binding of OSM and/or IL-31 to OSMR. In some embodiments, anti-OSMR antigen binding proteins are useful tools in studying diseases and disorders associated with OSMR and are particularly useful in methods of treating diseases and disorders associated with OSMR and binding of OSM and/or IL-31 to OSMR.
Abstract translation: 本发明提供抗制霉素M受体 - （OSMR）抗原结合蛋白。 例如抗体和功能片段，衍生物，突变蛋白及其变体。 OSMR抗原结合蛋白干扰OSM和/或IL-31与OSMR的结合。 在一些实施方案中，抗OSMR抗原结合蛋白是研究与OSMR相关的疾病和病症的有用工具，并且特别可用于治疗与OSMR和OSM和/或IL-31与OSMR结合的疾病和病症的方法。
-
公开(公告)号：US20160017042A1
公开(公告)日：2016-01-21
申请号：US14772863
申请日：2014-03-14
Applicant: BIOGEN MA INC.
Inventor： Shelia M. Violette , Paul H. Weinreb , Timothy David Jones , Francis Joseph Carr , Anja Sibylle Tessarz
CPC classification number: C07K16/2839 , C07K2317/14 , C07K2317/24 , C07K2317/565 , G01N33/5308 , G01N2800/00
Abstract: Humanized antibodies and antibody fragments thereof that bind to αvβ6 are disclosed. Also disclosed are methods of using these antibodies and antibody fragments to diagnose, treat, and/or prevent αvβ6-mediated diseases such as acute tissue injury, fibrosis, and cancer.
Abstract translation: 公开了结合αv＆bgr6的人源化抗体及其抗体片段。 还公开了使用这些抗体和抗体片段诊断，治疗和/或预防αvβb介导的疾病如急性组织损伤，纤维化和癌症的方法。
-
公开(公告)号：US20200262895A1
公开(公告)日：2020-08-20
申请号：US16580152
申请日：2019-09-24
Applicant: Biogen MA Inc. , Biogen International Neuroscience GmbH
Inventor： Paul H. Weinreb , Feng Chen , Ellen A. Garber Stark , Jan Grimm , Fabio Montrasio
Abstract: Provided are novel human tau-specific antibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for tau are also disclosed. The antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for tau targeted immunotherapy and diagnosis, respectively.
-
公开(公告)号：US20160159878A1
公开(公告)日：2016-06-09
申请号：US14952613
申请日：2015-11-25
Applicant: Biogen MA Inc.
Inventor： Daniel H.S. Lee , Dingyi Wen , R. Blake Pepinsky , Jane K. Relton , Xinzhong Wang , Alexey Lugovskoy , Werner Meier , Ellen A. Garber , Laura Silvian , Paul H. Weinreb
IPC: C07K14/705
CPC classification number: C07K14/705 , A01K67/027 , A01K67/0275 , A01K2217/058 , A01K2227/105 , A01K2267/0356 , A61K38/179 , A61K39/3955 , A61K48/00 , A61K2039/505 , C07K16/28 , C07K16/2863 , C07K2317/34 , C07K2317/55 , C07K2317/56 , C07K2317/76 , C07K2319/30 , C07K2319/32 , C07K2319/33 , C07K2319/74 , C12N15/1136 , C12N15/1138 , C12N15/8509 , C12N2310/111 , C12N2310/14 , C12N2310/53
Abstract: Disclosed are immunogenic Nogo receptor-1 polypeptides, Nogo receptor-1 antibodies, antigen-binding fragments thereof, soluble Nogo receptors and fusion proteins thereof and nucleic acids encoding the same. Also disclosed are Nogo receptor antagonist polynucleotides. Also disclosed are compositions comprising, and methods for making and using, such Nogo receptor antibodies, antigen-binding fragments thereof, soluble Nogo receptors and fusion proteins thereof, nucleic acids encoding the same and antagonist polynucleotides.
Abstract translation: 公开了免疫原性Nogo受体-1多肽，Nogo受体-1抗体，其抗原结合片段，可溶性Nogo受体及其融合蛋白和编码其的核酸。 还公开了Nogo受体拮抗剂多核苷酸。 还公开了包含这样的Nogo受体抗体，其抗原结合片段，可溶性Nogo受体及其融合蛋白，编码相同的核苷酸和拮抗剂多核苷酸的制备和使用方法。
-
公开(公告)号：US20190169274A1
公开(公告)日：2019-06-06
申请号：US16020346
申请日：2018-06-27
Applicant: Biogen MA Inc. , Biogen International Neuroscience GmbH
Inventor： Paul H. Weinreb , Feng Chen , Ellen A. Garber Stark , Jan Grimm , Fabio Montrasio
Abstract: Provided are novel human tau-specific antibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for tau are also disclosed. The antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for tau targeted immunotherapy and diagnosis, respectively.
-
-
-
-
-
-
-
-
-
Search Results
11
records
(took 0.023 seconds)
